105
WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri Mondor hospital Créteil, France [email protected] Frankfurt, Sept.10, 2015

WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Embed Size (px)

Citation preview

Page 1: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

WHAT DID WE DO IN FRANCE ?

(and perspectives…)

Daniel Dhumeaux, Henri Mondor hospital

Créteil, France

[email protected] Frankfurt, Sept.10, 2015

Page 2: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

The French masterplan : successive steps

1st national sero-

prevalence survey

1st national

programme

(HCV)

1994

Episodes of transmission in

health-care settings

High

prevalence

in DUs

law relative to

public health

policy

20041999 2002

2nd national

programme

(HCV+HBV)

Conference on

Hep C treatment

- National

seroprevalence

survey in DUs

- 2nd national sero-

prevalence survey

Hepatology

reference centre

implementation

2009-2012

3rd national

programme

(HCV+HBV)

Surveillance

19961997

Page 3: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

The French masterplan : successive steps

1st national sero-

prevalence survey

1st national

programme

(HCV)

1994

Episodes of transmission in

health-care settings

High

prevalence

in DUs

law relative to

public health

policy

20041999 2002

2nd national

programme

(HCV+HBV)

Conference on

Hep C treatment

- National

seroprevalence

survey in DUs

- 2nd national sero-

prevalence survey

Hepatology

reference centre

implementation

2009-2012

3rd national

programme

(HCV+HBV)

Surveillance

1996 1997

Page 4: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

The 30 HBV/HCV expert centers in France

Page 5: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

The French masterplan : successive steps

1st national sero-

prevalence survey

1st national

programme

(HCV)

1994

Episodes of transmission in

health-care settings

High

prevalence

in DUs

law relative to

public health

policy

20041999 2002

2nd national

programme

(HCV+HBV)

Conference on

Hep C treatment

- National

seroprevalence

survey in DUs

- 2nd national sero-

prevalence survey

Hepatology

reference centre

implementation

2009-2012

3rd national

programme

(HCV+HBV)

Surveillance

19961997

Page 6: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

The French masterplan : successive steps

1st national sero-

prevalence survey

1st national

programme

(HCV)

1994

Episodes of transmission in

health-care settings

High

prevalence

in DUs

law relative to

public health

policy

20041999 2002

2nd national

programme

(HCV+HBV)

Conference on

Hep C treatment

- National

seroprevalence

survey in DUs

- 2nd national sero-

prevalence survey

Hepatology

reference centre

implementation

2009-2012

3rd national

programme

(HCV+HBV)

Surveillance

19961997

Page 7: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

The French masterplan : successive steps

1st national sero-

prevalence survey

1st national

programme

(HCV)

1994

Episodes of transmission in

health-care settings

High

prevalence

in DUs

law relative to

public health

policy

20041999 2002

2nd national

programme

(HCV+HBV)

Conference on

Hep C treatment

- National

seroprevalence

survey in DUs

- 2nd national sero-

prevalence survey

Hepatology

reference centre

implementation

2009-2012

3rd national

programme

(HCV+HBV)

Surveillance

19961997

Page 8: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

The French masterplan : successive steps

1st national sero-

prevalence survey

1st national

programme

(HCV)

1994

Episodes of transmission in

health-care settings

High

prevalence

in DUs

law relative to

public health

policy

20041999 2002

2nd national

programme

(HCV+HBV)

Conference on

Hep C treatment

- National

seroprevalence

survey in DUs

- 2nd national sero-

prevalence survey

Hepatology

reference centre

implementation

2009-2012

3rd national

programme

(HCV+HBV)

Surveillance

19961997

Page 9: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

French medicine agencies

French national authority

of health

Ministry department in charge

of addiction prevention

National

committee

French national stake-houlders

Page 10: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

- More than 1,000 medicinal products assessed since 1994

- Availability 10 to 12 months before market authorization

application

- Therapeutic areas

. Oncology-haematology

. Central nervous system diseases

. Metabolic disorders

. Infectious diseases including HIV infection and

and viral hepatitis

- Implemented in 1994

The French of authorization for temporary use (ATU)

Page 11: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

French ATU for hepatitis C virus infection

. Boceprevir or telaprevir + peginterferon

+ ribavirin (CUPIC cohort)

. Sofosbuvir + ribavivin

. Simeprevir + peginterferon + ribavirin

. Sofosbuvir + daclatasvir

. Sofosbuvir + ledipasvir

. Paritaprevir/r + ombitasvir + dasabuvir

Page 12: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

The French masterplan : successive steps

1st national sero-

prevalence survey

1st national

programme

(HCV)

1994

Episodes of transmission in

health-care settings

High

prevalence

in DUs

law relative to

public health

policy

20041999 2002

2nd national

programme

(HCV+HBV)

Conference on

Hep C treatment

- National

seroprevalence

survey in DUs

- 2nd national sero-

prevalence survey

Hepatology

reference centre

implementation

2009-2012

3rd national

programme

(HCV+HBV)

Surveillance

19961997

Page 13: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

2014 French ministry guidelines

for the management of patients

with hepatitis B and C

Coordinator : Daniel Dhumeaux

Operators : ANRS and AFEF

Page 14: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

- Specific national committee for implementationand

monitoring (November 2014, French Ministry of Health)

- Initiated by the French Minister of Health

Management of patients with hepatitis B or C

virus infection. Report of recomendations

- Conducted beween April 2013 and May 2014

- Organized into expert groups on 22 themes

(from epidemiology to research), associated with

an independent committee for validation and synthesis

(200 people, including patients associations,

180 recommentations)

Page 15: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Defining strategic therapy

Page 16: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Sofosbuvir +

ribavirin

Daclatasvir +

asunaprevir +

beclabuvir

All-oral DAA availability in Europe

2015 2016

Sofosbuvir +

ledipasvir

Sofosbuvir +

daclastasvir

Sofosbuvir +

simeprevir

Paritaprevir/r +

dasabuvir +

ombitasvir

Grasoprevir +

elbasvir

Page 17: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Defining strategic therapy

Two planned successive steps

Page 18: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

2014 French ministery guidelines

for the management of patients

with hepatitis B and C

- Treat first patients with chronic hepatitis C :

. with fibrosis score of ≥ F2

. whatever the stage of fibrosis, with

extrahepatic manifestations, patients on a list

of organ transplantation, women who like to

get pregnant, and with the aim to collectively reduce

transmssion and epidemis, drugs users and prisoners.

Page 19: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri
Page 20: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Liver biopsy

n=2,110

Stage F3

n=336 (16%)

Stage F4

n=300 (14%)

Stage F2

n=618 (29%)

Cohort 2004-2011

n=14,256

Decomp. 27.7%

HCC 8.3%

Death 23.7%

Decomp. 10.1%

HCC 2.7%

Death 10.4%

Decomp. 3.6%

HCC 1.0%

Death 4.9%

Moorman et al. AASLD, Nov.2014 (Abstr. 174)

Morbidity and mortality of HCV infection at the

time of DAA (follow-up : 4 years)

Page 21: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Lee et al. J Infect Dis 2012;206:469-77

HCV chronic infection-induced mortality

Page 22: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Effects of HCV treatment on cardiovascular events

Nahon et al. JFHOD Paris, March 19 2015

Page 23: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Defining strategic therapy

The second step

Page 24: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Treating all patients

. HCV infection may induce long term severe hepatic

complications.

. HCV infection may induce (long term ?) severe

extrahepatic complications.

. Efficient oral treatment with low side effects and

expected low duration of administration may

prevent or treat these complications.

. Collectively, treating all patients is the best way for

reducing tansmission risk and limiting epidemics.

Page 25: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

2014 French ministery guidelines

for the management of patients

with hepatitis B and C

- Treat first patients with chronic hepatitis C :

- with fibrosis score of ≥ F2

- whatever the stage of fibrosis, with

extrahepatic manifestations, patients on a list

of organ transplantation, women who like to

get pregnant, drugs users, and prisoners.

- Then (2016?), provide treatment to all infected patients.

Page 26: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Burden of HCV infection in France

Infected patients

Treated patients (up to 2014)

Cured patients

Residual infected patients

200,000

70,000

35,000

165,000

Screened

100,000

To be screened

65,000

In treating 15,000 new patients each year, disease control

could be achieved within 10 years

Page 27: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri
Page 28: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Deuffic-Burban et al. Submitted for publication

Budgetary impact Treatment if ≥F2, with priority to>F3

< 20,000 patients treated /year

Page 29: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Decisions about price and reimbursement take

place at the level of each member state,

« considering the potential role/use of this

medicine in the context of the national health

system of that country ».

Reducing the cost of treatment

Page 30: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Costs of treatment have to be reduced

Page 31: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Screening

Page 32: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

50

100

0

-

-

-

HCV screening rates in European countries

65%

40% 40%33%

37%30%

50%

(%)

Page 33: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Screening

Evaluation

Treatment

Page 34: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Screening strategies according to

epidemiological studies

- USA : 1945-1965 birth cohort screening

- France…

- Canada : 1945-1975 birth cohort screening

Page 35: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Estimated proportion of persons between 18 to 60

year-old unaware of their HBV or HCV chronic

infection according to gender in France

Men MenWomen Women

HBV HCV

0

100

50 -

-

-

75%

25%

10%

90%

(%)

Page 36: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Proposed screening strategy in France

- All men between 18-60 years old

- Including combined detection of HBV, HCV

and HIV

Page 37: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

To screen and treat

Page 38: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri
Page 39: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Licensing Agreements to Increase Access to

Hepatitis C Treatments

Page 40: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri
Page 41: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

http://www.gilead.com/news/press-releases/2014/9/gilead-announces

-generic-licensing-agreements-to-increase-access-to-hepatitis-c-treatments

developing-countries

Licensing Agreements to Increase Access to

Hepatitis C Treatments in Developing Countries

Page 42: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

SVR

(%)

4 weeks 6 weeks 8 weeks6 weeksNo cirrhosis Cirrhosis

100

50

0

95%

80%87%

39%

Grasoprevir +elbasuvir + sofosbuvir in patients

with naïve patients with genotype1

Lawitz et al. AASLD 2014, Abstr. LB-33

31 30 20 19

Page 43: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Hepatitis C worldwide

. Annual mortality : 350,000

. Prevalence of viremic people : 130 millions

. Prevalence of infected people : 170 millions

Page 44: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri
Page 45: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

-

-

-

IFN24 IFN48 IFN-RBV24IFN-RBV48 PEG IFN-

RBV48

PEG IFN-

RBV-DAA1

0

50

100

Advances in therapy (hepatitis C virus genotype 1)

SVR

(%)

7%2%

16%

75%

40%

28%

90%

DAA

Page 46: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Cumulative treatment rate in 21 country, according

to national sources of prevalence

Lettmeier et al. J Hepatol 2008

Page 47: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri
Page 48: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Decisions about price and reimbursement take

place at the level of each member state,

« considering the potential role/use of this

medicine in the context of the national health

system of that country ».

Page 49: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Criteria for granting ATU

1. The product is a medicinal product (not a preparation)

3. There is no market authorisation application

2. ATU is given for treatment (not for investigation)

6. There is no available alternative therapeutic method

7. Efficacy and safety are presumed and benefit is

expected for the patient

4. The patient cannot be included in a clinical trail

5. The disease is serious and/or rare

Page 50: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Two types of ATU : nominative and cohort ATU

Nominative ATU

. For one patient, on a name

patient basis

. On the request and

responsibility of the clinician

. ATU for the duration of

treatment

. Usually follow-up of patients

and data collection according

to a protocol for therapeutic use

Cohort ATU

. For a group of patients

. Applied by the company

commitment to submit a

marketing autorisation

. ATU for one-year duration,

renewal possible

. Always follow-up of patients

and data collection according

to a protocol of therapeutic use

Page 51: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

The ATU system : success and limits

- The ATU system is extremely useful for covering public

health needs :

. It is strongly supported by patients ans physicians

. It is contolled by competent authorities (*)

- The risks are (a) to slow down clinical trials and

marketing autorisation applications, (b) to overestimate

efficacy and to underestimate safety

- Regarding nominative ATU :

. Too many

. Complex system

. No strong regulatory long term status (no mandatory

marketing authorisation application)

(*) ansm : agence nationale de sécurité du médicament et des produits de santé

Page 52: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

N NN Engl J Med 2014, April 10

Page 53: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Screening strategies according to

epidemiological studies

- USA : 1945-1965 birth cohort screening

- France :

. men between 18 and 60-year old

. combined detection of HCV, HBV and HIV

- Canada : 1945-1975 birth cohort screening

Page 54: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Screening strategies according to

epidemiological studies

- USA : 1945-1965 birth cohort screening

- France…

- Canada : 1945-1975 birth cohort screening

Page 55: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Screening rate of hepatitis C in European countries

Deuffic-Burban et al. Gastroenterology 2012; 143:974-85

Page 56: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Deuffic-Burban et al. Gastroenterology 2012;143:974-85

Page 57: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

2014 French ministery guidelines

for the management of patients

with hepatitis B and C

- Treat first patients with chronic hepatitis C :

- with fibrosis score of ≥ F2

- whatever the stage of fibrosis, with

extrahepatic manifestations, patients on a list

of organ transplantation, women who like to

get pregnant, drugs users, and prisoners.

Page 58: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Premature ovarian senescence in HCV-positive

women of child-bearing age

Antimullerian hormone

(AMH)

ControlControl HCVHCV

AMH levels indicative of

ovarian failure (i.e. <0.8ng/ml)

15

5

10

0

-

-

-

-

13.0

3.210

30

20

0

-

-

-

-

28.0

9.7

(ng/ml)

Karampatou et al. AASLD, Boston 2014

Page 59: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri
Page 60: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Epidemiologie inter-régionale de l’hépatite C

Page 61: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri
Page 62: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri
Page 63: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Paritaprevir/r + ombitasvir + dasabuvir + ribavirin

Side effects

Side effects

Fatigue

Nausea

Pruritus

Insomnia

Diarrhea

33D+RBV

Placebo

0 20 40 60 80 100

Feld et al. N Engl J Med 2014

Headache

Page 64: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Cognitive emotional and functional brain impairment

(«brain fog») in hepatitis C chronic infection.

Afdal et al. AASLD 2014 (Abstr. 48)

1. DAA treatment induced an increase in basal

ganglia n-acetyl aspartate (NAA)/creatine (Cr) ratio

in all patients at magnetic resonance spectroscopy.

Effect of sofosbuvir-ledipasvir ± ribavirin in 14

patients with genotype 1 and F0-F1 fibrosis

2. The effect was more apparent in patients

not receiving ribavirin.

3. Some of the changes in basal ganglia correlated

with changes in the emotiotonal function domain of

CLDQ-HCV and in the mental health scale of SF-36.

Page 65: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri
Page 66: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Patient-reported outcomes (PRO) after 12 weeks

of treatment by sofosfuvir and ledipasvir

Younoussi et al. EASL 2014 (Abstr. P1324)

0.95

0.65

0.80

Quality

of life

Page 67: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Proposed screening strategy in France

- All men between 18-60 years old

- including combined detection of HBV, HCV

and HIV

Page 68: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Proposed screening strategy fo HBV

and HCV in France

2. Extend testing to all men between 18-60

years old

3. Propose combined detection of HBV, HCV

and HIV

1. Reinforce the strategy of targeted testing

based on risk of contamination

Page 69: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Yonoussi et al. AASLD, Boston 2014

Patient-reported outcomes (PRO) after 12 weeks

of treatment by sofosfuvir and ledipasvir

Page 70: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Treating

Page 71: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

« THE FRENCH EXPERIENCE »

Daniel Dhumeaux, Henri Mondor hospital

Créteil, France

[email protected] Glasgow, Dec.11, 2014

Page 72: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Wiesse et al. Hepatology 2014

Page 73: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri
Page 74: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri
Page 75: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri
Page 76: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri
Page 77: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri
Page 78: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Sofosbuvir DaclatasvirSimeprevir

New direct-acting antivirals

(May 2014)(Jan. 2014) (Sept.2014)

High genetic barrier

of resistance

Low genetic barrier

of resistance Low barrier genetic

of resistance

Genotypes 1,2,4 Genotype 1b All genotypes

Sofosbuvir+

ledipasvir

(Nov. 2014)

Low genetic barrier

of resistance

All genotypes (suboptimal in GT3)

Page 79: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri
Page 80: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Sofosbuvir +

ribavirin

All-oral DAA availability in Europe

Now

Sofosbuvir +

ledipasvir

Sofosbuvir +

daclastasvir

Sofosbuvir +

simeprevir

Page 81: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

http://www.gilead.com/news/press-releases/2014/9/gilead-announces

-generic-licensing-agreements-to-increase-access-to-hepatitis-c-treatments

developing-countries

Licensing Agreements to Increase Access to

Hepatitis C Treatments in Developing Countries

Page 82: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Deuffic-Burban et al. Gastroenterology 2012;143:974-85

Page 83: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri
Page 84: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Sofosbuvir DaclatasvirSimeprevir

New direct-acting antivirals

(May 2014)(Jan. 2014) (Sept.2014)

High genetic barrier

of resistance

Low genetic barrier

of resistance Low barrier genetic

of resistance

Genotypes 1,2,4 Genotype 1b All genotypes

Sofosbuvir+

ledipasvir

(Nov. 2014)

Low genetic barrier

of resistance

All genotypes (suboptimal in GT3)

Page 85: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Sofosbuvir DaclatasvirSimeprevir

New direct-acting antivirals

(May 2014)(Jan. 2014) (Sept.2014)

High genetic barrier

of resistance

Low genetic barrier

of resistance Low barrier genetic

of resistance

Genotypes 1,2,4 Genotype 1b All genotypes

Sofosbuvir+

ledipasvir

(Nov. 2014)

Low genetic barrier

of resistance

All genotypes (suboptimal in GT3)

Page 86: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri
Page 87: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Five-year of death (all causes) or hepatocellular

carcinima in HCV patients with ( ) or without ( ) SVR.

Meta-analysis of 129 studies in 23,309 patients

Hill et al. AASLD 2014 (Abstr.44)

General Cirrhotic CoinfectedCoinfectedCirrhotic General

Patients

(%)

15

0

5

10

-

-

-

-

10.5 11.3

4.53.6

1.3

10.0

2.9

9.3

13.9

5.3

0.9

10.0

Death Hepatocellular carcinoma

Page 88: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Decisions about price and reimbursement take

place at the level of each member state,

« considering the potential role/use of this

medicine in the context of the national health

system of that country ».

Page 89: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Screening strategies according to

epidemiological studies

- USA : 1945-1965 birth cohort screening

- France :

. all men between 18 and 60-year old

. combined detection of HCV, HBV and HIV

- Canada : 1945-1975 birth cohort screening

Page 90: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Five-year of death (all causes) or hepatocellular

carcinima in HCV patients with ( ) or without ( ) SVR.

Meta-analysis of 129 studies in 23,309 patients

Hill et al. AASLD 2014 (Abstr.44)

General Cirrhotic CoinfectedCoinfectedCirrhotic General

Patients

(%)

15

0

5

10

-

-

-

-

10.5 11.3

4.53.6

1.3

10.0

2.9

9.3

13.9

5.3

0.9

10.0

Death Hepatocellular carcinoma

Page 91: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Kwong et al. PLUS ONE 2012;7:e44103

Impact of infectious diseases on healthThe Ontario Burden of Infectious Diseases Study (ONBOIDS)

Health-adjusted life year (HALY)

Page 92: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Hepatitis B Hepatitis C

Prevalence Anti-HCV Ab:0.84%

Annual mortality

Proportion of

sceened people

Number of infected

people 280 000

HCV RNA:0.53%

InVS 2004

HBsAg:0.65%

57%45%

230 000

2 6001 300

Marcellin et al. J Hepatol 2008;48:200-7

Page 93: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Hepatitis B Hepatitis C

Prevalence Anti-HCV Ab:0.84%

Annual mortality

Proportion of

sceened people

Number of infected

people 280 000

HCV RNA:0.53%

InVS 2004

HBsAg:0.65%

57%45%

230 000

2 6001 300

Marcellin et al. J Hepatol 2008;48:200-7

Page 94: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Hepatitis B Hepatitis C

Prevalence Anti-HCV Ab:0.84%

Annual mortality

Proportion of

sceened people

Number of infected

people 280 000

HCV RNA:0.53%

InVS 2004

HBsAg:0.65%

57%45%

230 000

2 6001 300

Marcellin et al. J Hepatol 2008;48:200-7

Page 95: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Lee et al. J Infect Dis 2012;206:469-77

HCV chronic infection-induced mortality

Page 96: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

HCV chronic infection-induced mortality

Lee et al. J Infect Dis 2012;206:469-77

Page 97: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Effects of treatment in patients with HCV cirrhosis

Nahon et al. JFHOD Paris, March 19 2015

Page 98: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Deuffic-Burban et al. Submitted for publication

Budgetary impact Treatment if ≥F2, with priority to>F3

< 20,000 patients treated /year

Page 99: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Deuffic-Burban et al. Submitted for publication

Budgetary impact Treatment if ≥F2, with priority to>F3

< 20,000 patients treated /year

Page 100: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

All patients Child-Pugh B Child-Pugh C

Sofosbuvir + ledipasvir + ribavirin in patients with

decompensated cirrhosis

Flamm et al. AASLD Boston 2014, Abstr. 239

100

50

0

-

--

87%89%

87%89%

86%

90%

SVR12

(%)12w

24w

Page 101: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

SOF + LDV +RBV

(12 weeks)

SOF + LDV

(24 weeks)

96% 97%

Bourlière et al. AASLD 2014, LB-6

100

50

0

SVR12

(%)

-

-

-

Effect of sofosbuvir + ledispasvir ± ribavirin in

cirrhotic patients with failure to

previous first-generation protease inhibitor regimen

Page 102: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

Fighting against hepatitis C

Page 103: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri

French national stake-holders

7

National

institute

of health & medical

Research

INSERM

National

Health

insurance

CNAM

French medicines

Agency

ANSM

Ministry department in charge

of addiction prevention

MILDT

National

Agency

for viral hepatitis

research

ANRS

Patients &

professionalsAssociations

Other Ministries

( economy,

employment,

housing, justice)

French national

authority for health

HAS

Ministry

of Social Affairs

and Health

Institute for

public health

surveillance

InVS

National

institute

for prevention &

health education

INPES

National

society

of blood

transfusion

EFS

Experts

Follow-up &

ProspectiveCommittee

Health

regional agencies

ARS

Page 104: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri
Page 105: WHAT DID WE DO IN FRANCE - Virology Educationregist2.virology-education.com/2015/1euhep/12_Dhumeaux.pdf · WHAT DID WE DO IN FRANCE ? (and perspectives…) Daniel Dhumeaux, Henri